Clinical trial
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
NCT00363168 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00363168 |
|---|---|
| Title | Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial |
| Official title | Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial |
| Lead sponsor | Johns Hopkins University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 7 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Aug 15, 2006 |
| Last update posted | Oct 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: